{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:03:55Z","timestamp":1784783035243,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":173,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000646","name":"JSPS","doi-asserted-by":"publisher","award":["24K18642"],"award-info":[{"award-number":["24K18642"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tsuchiya Memorial Medical Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Eosinophilic granulomatosis with polyangiitis is a heterogeneous vasculitic and eosinophilic disorder in which patients who are positive for myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) often develop glomerulonephritis and peripheral neuropathy and may require prolonged immunosuppressive therapy. Although rituximab (RTX) and mepolizumab have been used in selected patients with eosinophilic granulomatosis with polyangiitis, relapse during RTX maintenance remains difficult to manage. We report the case of a 59-year-old woman with adult-onset asthma and chronic rhinosinusitis who presented with severe eosinophilia, mononeuritis multiplex, MPO-ANCA positivity, and pauci-immune necrotising glomerulonephritis. Induction therapy with high-dose glucocorticoids, intravenous immunoglobulin, and RTX achieved clinical remission and allowed the tapering to a low dose of prednisolone. Despite RTX maintenance, she later relapsed with recurrent sinonasal symptoms, worsening neuropathic complaints, and a marked rise in MPO-ANCA levels. In this setting, a further escalation of immunosuppression during maintenance, including cyclophosphamide, may be considered; however, given the possibility that residual eosinophilic inflammation contributed to ongoing disease activity, including autoantibody production, mepolizumab was added after retreatment with RTX as sequential therapy. Symptoms stabilised and improved over the subsequent months, MPO-ANCA titres progressively declined to the normal range, and prednisolone was discontinued. Remission has been maintained on mepolizumab without further RTX maintenance. This case suggests that sequential eosinophil-targeted therapy may help consolidate remission after a relapse during RTX maintenance in MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis.<\/jats:p>","DOI":"10.1093\/mrcr\/rxag050","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:36:32Z","timestamp":1782214592000},"source":"Crossref","is-referenced-by-count":0,"title":["Mepolizumab add-on after relapse during rituximab maintenance in myeloperoxidase-antineutrophil cytoplasmic antibodies-positive eosinophilic granulomatosis with polyangiitis: A case report and literature review"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0558-8814","authenticated-orcid":false,"given":"Genki","family":"Kidoguchi","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-3430","authenticated-orcid":false,"given":"Michinori","family":"Ishitoku","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-9081","authenticated-orcid":false,"given":"Tomohiro","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-0509","authenticated-orcid":false,"given":"Yusuke","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-9943","authenticated-orcid":false,"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2026072300520704700_ref1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"2026072300520704700_ref2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1164\/rccm.202005-1628SO","article-title":"International consensus on antineutrophil cytoplasm antibodies testing in eosinophilic granulomatosis with polyangiitis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072300520704700_ref3","doi-asserted-by":"crossref","first-page":"102737","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2026072300520704700_ref4","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2026072300520704700_ref5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026072300520704700_ref6","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026072300520704700_ref7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026072300520704700_ref8","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026072300520704700_ref9","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7326\/ANNALS-24-03947","article-title":"Rituximab versus conventional therapy for remission induction in eosinophilic granulomatosis with polyangiitis: a randomized controlled trial","volume":"178","author":"Terrier","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026072300520704700_ref10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026072300520704700_ref11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/mrcr\/rxab022","article-title":"Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Higashitani","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"2026072300520704700_ref12","first-page":"112","article-title":"Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: a case report","volume":"26","author":"Shiroshita","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"2026072300520704700_ref13","doi-asserted-by":"publisher","first-page":"e9242","DOI":"10.7759\/cureus.9242","article-title":"Concurrent use of mepolizumab and rituximab for eosinophilic granulomatosis with polyangiitis and multisystem involvement","volume":"12","author":"Afiari","year":"2020","journal-title":"Cureus."},{"key":"2026072300520704700_ref14","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/ard-2022-222776","article-title":"Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study","volume":"81","author":"Bettiol","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026072300520704700_ref15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.63032\/OWCP6172","article-title":"Eosinophilic granulomatosis with polyangiitis treated with mepolizumab and rituximab combination therapy \u2013 a case report","volume":"4","author":"Moniz","year":"2025","journal-title":"ARP Rheumatol"},{"key":"2026072300520704700_ref16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10067-025-07808-y","article-title":"Glucocorticoid-free remission with simultaneous mepolizumab and rituximab in life-threatening PR3-ANCA-positive eosinophilic granulomatosis with polyangiitis: a case report and literature review","volume":"45","author":"Yamane","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026072300520704700_ref17","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00296-021-04950-z","article-title":"Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review","volume":"42","author":"Mutoh","year":"2022","journal-title":"Rheumatol Int"},{"key":"2026072300520704700_ref18","article-title":"Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission","volume":"75","author":"Lammoglia","year":"2023","journal-title":"Reumatismo."},{"key":"2026072300520704700_ref19","doi-asserted-by":"publisher","first-page":"e38797","DOI":"10.7759\/cureus.9242","article-title":"Successful treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a case report","volume":"15","author":"Pe\u00f1a","year":"2023","journal-title":"Cureus."},{"key":"2026072300520704700_ref20","doi-asserted-by":"publisher","first-page":"e70186","DOI":"10.1002\/rcr2.70186","article-title":"Relapse of eosinophilic granulomatosis with polyangiitis (EGPA) despite maintenance treatment with low-dose mepolizumab","volume":"13","author":"Vanthuyne","year":"2025","journal-title":"Respirol Case Rep"},{"key":"2026072300520704700_ref21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.alit.2023.09.001","article-title":"Reduction in ANCA levels associated with mepolizumab add-on treatment in eosinophilic granulomatosis with polyangiitis: case series and literature review","volume":"73","author":"Kamide","year":"2024","journal-title":"Allergol Int"},{"key":"2026072300520704700_ref22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","article-title":"Eosinophils in vasculitis: characteristics and roles in pathogenesis","volume":"10","author":"Khoury","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2026072300520704700_ref23","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/art.41727","article-title":"Eosinophil ETosis\u2013mediated release of galectin-10 in eosinophilic granulomatosis with polyangiitis","volume":"73","author":"Fukuchi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026072300520704700_ref24","doi-asserted-by":"publisher","first-page":"801897","DOI":"10.3389\/fimmu.2021.801897","article-title":"Increased circulating cell-free DNA in eosinophilic granulomatosis with polyangiitis: implications for eosinophil extracellular traps and immunothrombosis","volume":"12","author":"Hashimoto","year":"2022","journal-title":"Front Immunol"},{"key":"2026072300520704700_ref25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ni.1981","article-title":"Eosinophils are required for the maintenance of plasma cells in the bone marrow","volume":"12","author":"Chu","year":"2011","journal-title":"Nat Immunol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxag050\/68586370\/rxag050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/2\/rxag050\/68586370\/rxag050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/2\/rxag050\/68586370\/rxag050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:52:34Z","timestamp":1784782354000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxag050\/8714110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxag050","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rxag050"}}